News >

Binimetinib/Encorafenib Positive OS Data Released as FDA Weighs Melanoma Approval

Jason M. Broderick @jasoncology
Published: Tuesday, Feb 06, 2018

Dr. Keith T. Flaherty

Keith T. Flaherty, MD
Treatment with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with BRAF-mutant advanced, unresectable or metastatic melanoma, according to updated findings from the phase III COLUMBUS trial.

The combination of encorafenib at 450 mg daily and binimetinib at 45 mg twice daily reduced the risk of death by 39% versus vemurafenib monotherapy (hazard ratio [HR], 0.61; 95% CI 0.47-0.79; P <.001).1 The median overall survival was 33.6 months versus 16.9 months, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication